Nasdaq
$4.10▲ 1.49%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $328.1MShares out 80.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
3- 10.6After-hours26.10.07 07:20SCHEDULE 13GOwnership#●●●
Atea Pharmaceuticals, Inc.
Tang Capital Management and its affiliated entities have filed a Schedule 13G regarding their collective ownership of Atea Pharmaceuticals common stock. This filing formalizes the joint holding of the company's shares by multiple investment vehicles managed by Kevin Tang.…more
$4.10+1.49%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.12After-hours26.08.13 05:4510-QEarnings
Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals updated its non-employee director compensation program effective June 18, 2026, granting 129,200 stock options to new directors and annual awards of 37,700 stock options and 26,700 restricted stock units to existing directors. Additionally, the company entered into a consulting agreement with Bruno Lucidi on June 1, 2026, for a quarterly fee of $25,000 to provide advisory services regarding international product commercialization and pricing.…more
$4.10+1.49%vs prev closeView filingShare - 8.12After-hours26.08.13 05:158-KKey event
Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals reported its Q2 2026 financial results and announced that its Phase 3 C-BEYOND trial for the BEM/RZR regimen met its primary endpoint. The company expects top-line results from the C-FORWARD Phase 3 trial in early Q1 2027 and plans to submit an NDA to the FDA in Q2 2027. As of June 30, 2026, the company held $219.46 million in cash and investments, with a net loss of $32.93 million for the second quarter.…more
$4.10+1.49%vs prev closeView filingShare
2 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.8Pre-market26.09.08 20:00#●●●#●●●
Atea Pharmaceuticals to Present at Morgan Stanley Healthcare Conference…more
Atea Pharmaceuticals announced that its management team will present at the 24th Annual Morgan Stanley Global Healthcare Conference. This event is a standard investor presentation and does not contain material financial news.…more
$4.10+1.49%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.12After-hours26.08.13 05:05
●●●●●●●● ●●●●● ●●●●●●
Atea Pharmaceuticals has released its financial results for the second quarter of 2026 along with a business update. Investors can assess the company's current financial position and strategic outlook through this disclosure.…more
$4.10+1.49%vs prev close - 8.5Pre-market26.08.05 20:00
●●●●●●●● ●●●●● ●●●●●●
아테아 파마슈티컬스가 오는 8월 12일 2분기 재무 실적 발표 및 사업 업데이트를 위한 컨퍼런스 콜을 진행합니다. 투자자들은 이번 발표를 통해 회사의 주요 파이프라인 진행 상황과 향후 사업 방향을 확인할 수 있습니다.…more
$4.10+1.49%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report